AgingResearch.NewsJoin free
Acta Obstetricia et Gynecologica Scandinavica

Hormone therapy after ovarian cancer not linked to worse survival

For epithelial ovarian cancer, which starts in lining cells, adjusted 10-year survival was 52.4% among hormone users versus 51.7% among non-users.

Paper by Åsa Ehlin von Kartaschew, Pernilla Dahm-Kähler, Kenny Alexandra Rodriguez-Wallberg, Erik C. Holmberg, Angelique Flöter-Rådestad · Karolinska Institutet · Karolinska University Hospital

Our read

Populations
Studied:
Cohort study of 454 women with epithelial ovarian cancer, median 11.7 years
What changed:
Following ovarian cancer surgery, 10-year survival did not differ: 52.4% with hormone therapy versus 51.7% without it
The catch:
Smoking, BMI, and other illnesses affecting survival were missing from the analysis
In the record:
The 366th paper on hormone replacement therapy with results in people; 983 on record in all.

Editor of record: Boris Djordjevic · AgingResearch.News

Paper
Follow @agingbrief

Premenopausal women in Sweden—779 aged 18–50—were followed in a nationwide observational cohort after both ovaries and fallopian tubes were removed for ovarian cancer or borderline ovarian tumors. Their median age was 45, and median follow-up was 11.7 years. Prescription records identified hormone dispensing from one month before surgery through five years afterward.

Among 472 women with epithelial ovarian cancer, which starts in lining cells, hormone use was not associated with worse 10-year survival. Survival estimates accounted for cancer stage and whether surgery left any tumor. The uncertainty range included both lower and higher mortality. Among 239 women with borderline tumors, which lack invasive growth, 10-year survival was 96.2% in hormone users versus 95.3% in non-users. Too few deaths occurred to analyze survival in 68 women with other ovarian cancer types.

Why it matters

Surgical menopause brings an age-related hormonal transition forward for young ovarian cancer survivors. Long-term survival is an important consideration when weighing hormone therapy in this setting.

Caveats

Hormone users with epithelial cancer were younger, and other differences between users and non-users may have influenced survival despite adjustment. The findings do not cover women over 50 or those with current or past breast or endometrial cancer.

From the paper

Participants

We identified 805 women between 18 and 50 years of age who had a BSO performed due to OC during the study period.

RESULTS

Result

In the predictions from the regression model, adjusted for FIGO stage I‐II versus III‐IV and residual disease or not at surgery, for women with an EOC (n = 454), the 5‐year OS for the postoperative MHT users was 67.1% (95% CI 61.9–72.8) versus 66.5% (95% CI 62.7–70.6) for the non‐users.

Results, Survival in EOC following postoperative MHT use

Quoted word for word from the full text on PubMed Central.

Comments

Be the first to comment.

More on Hormone replacement therapy